Evidence map›Paper›PMID 41310554›Full record

ArticleBMC endocrine disorders2025

Metabolically healthy obesity increases the risks of MASLD and hyperuricemia: a cohort study with mediation analysis.

Yiyun Liu, Tianchen Qian, Yiyang Zheng, Aiming Liu, Lei Xu, Guoliang Ye, Jiarong Xie

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07001865 (Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07001865 enrolling by invitationnot on this map

Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia: A Cohort Study With Mediation Analysis

TypeobservationalSponsorNingbo No. 1 HospitalRan2025 to 2025Enrolled17,040ConditionsMetabolic Dysfunction-Associated Steatotic Liver Disease, Metabolically Healthy Obesity, Hyperuricemia
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yiyun LiuDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, No.59. Liuting Street, Haishu District, Ningbo, 315000, China.
Tianchen QianDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, No.59. Liuting Street, Haishu District, Ningbo, 315000, China.
Yiyang ZhengDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, No.59. Liuting Street, Haishu District, Ningbo, 315000, China.
Aiming LiuHealth Science Center, Ningbo University, Ningbo, Zhejiang, 315211, China.
Lei XuDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, No.59. Liuting Street, Haishu District, Ningbo, 315000, China. xulei22@163.com.
Guoliang YeDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, No.59. Liuting Street, Haishu District, Ningbo, 315000, China. yeguoliang@nbu.edu.cn.
Jiarong XieDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, No.59. Liuting Street, Haishu District, Ningbo, 315000, China. cheryl.xiejiarong@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough metabolically healthy obesity (MHO) is often regarded as a relatively benign phenotype, its association with the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and hyperuricemia remains unclear. This study examined the associations between MHO and other metabolic-obesity phenotypes with MASLD and hyperuricemia, and explored the mediating roles of metabolic indicators.

methodsThis study included 11,712 and 13,846 participants from a health examination cohort at the First Affiliated Hospital of Ningbo University for MASLD and hyperuricemia analyses, respectively. Participants were classified into four metabolic-obesity phenotypes, with MHO defined as obesity without metabolic syndrome components. Cox regression and mediation analyses were performed to examine the associations and the proportions explained by metabolic indicators.

resultsDuring a 7-year follow-up period, 3,756 MASLD and 3,294 hyperuricemia cases were identified. Compared with the metabolically healthy non-obese group, individuals with MHO exhibited significantly higher risks of MASLD (hazard ratio [HR] = 3.54, 95% confidence interval [CI]: 3.09–4.05) and hyperuricemia (HR = 1.92, 95% CI: 1.65–2.23). Mediation analysis illustrated that the triglyceride glucose index accounted for 16.2% and 13.8% of the total effects, while other indicators also contributed to the associations to varying degrees.

conclusionMHO is associated with an increased risk of MASLD and hyperuricemia, partly explained by metabolic indicators. Greater attention to these indicators may facilitate earlier risk identification and more effective prevention. CLINICAL

trial registrationNCT07001865; Registration date: May 25, 2025; ClinicalTrials.gov.

Indexed as

HyperuricemiaNon-alcoholic Fatty Liver DiseaseObesity, Metabolically BenignAdultChinaCohort StudiesFemaleFollow-Up StudiesHumansMaleMediation AnalysisMiddle AgedPrognosisRisk FactorsHyperuricemiaMASLDMediation analysisMetabolically healthy obesityMetabolic indicators

Identifiers

PMID41310554
PMCPMC12763833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.